Status:

COMPLETED

Ascending Multi-dose Study of REGN727(SAR236553) With and Without Concomitant Atorvastatin

Lead Sponsor:

Regeneron Pharmaceuticals

Collaborating Sponsors:

Sanofi

Conditions:

Hypercholesterolemia

Eligibility:

All Genders

18-65 years

Phase:

PHASE1

Brief Summary

This study will test the safety, tolerability, and bioeffects (how the body reacts to the drug) of REGN727 compared with placebo (an inactive substance that contains no medicine) in hyperlipidemic pat...

Eligibility Criteria

Inclusion

  • Inclusion Criteria
  • Men and women with elevated cholesterol on stable doses of atorvastatin 10-40mg/day regimen
  • Body mass index between 18.0 and 35.0 kg/m2, inclusive
  • For women of childbearing potential, a negative serum pregnancy test at the screening visit and a negative urine pregnancy test on day -2 or day -1
  • For men and women of childbearing potential, willingness to utilize adequate contraception and not become pregnant (or have their partner\[s\] become pregnant)during the full duration of the study
  • Willing, committed and able to return for all the clinic visits and complete all study-related procedures
  • Able to read, and able to sign the informed consent form
  • Exclusion Criteria:
  • History of MI, ACS, Angina, Stroke, peripheral vascular disease, or cardiac revascularization
  • Pregnant or breast-feeding women
  • Blood donation of any volume within 1 month prior to administration of study drug
  • Congestive heart failure
  • Consumption of greater than 1 quart of grapefruit juice per day
  • Previous exposure to any therapeutic or investigational biological agent within 30 days of screening
  • History of alcohol or drug abuse within one year to the screening visit
  • The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.

Exclusion

    Key Trial Info

    Start Date :

    June 1 2010

    Trial Type :

    INTERVENTIONAL

    Allocation :

    ACTUAL

    End Date :

    May 1 2011

    Estimated Enrollment :

    72 Patients enrolled

    Trial Details

    Trial ID

    NCT01161082

    Start Date

    June 1 2010

    End Date

    May 1 2011

    Last Update

    January 27 2015

    Active Locations (2)

    Enter a location and click search to find clinical trials sorted by distance.

    Page 1 of 1 (2 locations)

    1

    Site 1

    Cincinnati, Ohio, United States

    2

    Site 2

    Knoxville, Tennessee, United States